Can a new injection tame Gout's uric acid?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Fully informed and signed the Informed Consent Form (ICF); * Diagnosed with gout per the 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria, with a screening serum uric acid (sUA) level ≥7.0 mg/dL, and in a non-acute phase at the time of first dose; * Aged 18-70 years (inclusive), male or female; * Body mass index (BMI) ≥18.5 kg/m²; * Failure to achieve sUA \<7.0 mg/dL after ≥8 weeks of standardized treatment with conventional urate-lowering therapy (ULT) (effective doses include but are not limited to: allopurinol ≥300 mg/day, febuxostat ≥40 mg/day, or benzbromarone ≥50 mg/day; investigators may adjust doses based on tolerance and renal/hepatic function) OR contraindication/intolerance to ULT; No use of oral urate-lowering drugs within 1 week prior to randomization; * Negative serum pregnancy test for women of childbearing potential; * Agreement by subjects and their partners of childbearing potential to use highly effective contraception or practice abstinence during the study and for 6 months after the last dose; * Ability to understand and comply with protocol requirements; investigators anticipate completion of the entire study. Exclusion Criteria: * Intolerance to multiple intramuscular injections. * Known hypersensitivity to the investigational drug, PEG-containing drugs, NSAIDs (e.g., ibuprofen, acetaminophen), or therapeutic protein products (e.g., fresh/frozen plasma, human serum albumin, cytokines, interleukins). * History of severe allergic reactions or hypersensitivity to foods, inhalants, contact substances, or drugs, or being allergy-prone (multiple drug/food allergies). * Acute gout flare within 2 weeks prior to baseline. * History of organ transplantation requiring immunosuppressive therapy. * Use of prednisone \>10 mg/day (or equivalent) within 1 week prior to screening. * Contraindications to antihistamine use. * History of severe diseases (digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematologic, or immune systems) within 3 months prior to screening. * New or worsening coronary artery disease or congestive heart failure within 3 months prior to screening, or history of: 1. Acute coronary syndrome (e.g., acute myocardial infarction \[AMI\], unstable angina). 2. Coronary interventions (e.g., CABG, PTCA). 3. Stroke or transient ischemic attack. * Uncontrolled hypertension (resting systolic blood pressure \[SBP\] ≥180 mmHg and/or diastolic blood pressure \[DBP\] ≥110 mmHg). Exception: Subjects with controlled blood pressure after adjustment of antihypertensives per guidelines may be enrolled if rechecked during screening. * Severe peripheral vascular disease (e.g., disabling claudication, unhealed ischemic ulcers, or conditions requiring surgery/angioplasty). * Poorly controlled diabetes (HbA1c \>9.0%). * Vaccination within 1 month prior to baseline or plans to receive non-inactivated vaccines during the study. Note: Inactivated vaccines require a 2-week interval from study drug administration. * Active malignancy or history of malignancy within 5 years prior to screening (exceptions: basal/squamous cell skin cancer, excised cervical intraepithelial neoplasia, or carcinoma in situ). * History of glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD level below the lower limit of normal. Testing sources: Results from the study site, tertiary hospitals, or Guangzhou Kingmed Center for Clinical Laboratory Co., Ltd. are acceptable. Sample disposal: Processed by Guangdong Environmental Living Waste Disposal Center Co., Ltd. * Laboratory abnormalities: A. Hemoglobin \<10 g/dL. B. Active hepatitis B (HBsAg+ with HBV DNA ≥500 IU/mL or 2500 copies/mL), HCV antibody+, HIV antibody+, or syphilis antibody+ (RPR/TPPA+). C. White blood cells \<3.0×10⁹/L. D. Platelets \<75×10⁹/L. E. ALT/AST \>3× upper limit of normal (ULN). * Participation in conflicting clinical trials (device or PEG/uricase-based drugs) within 12 weeks prior to screening. * Participation in other drug-intervention trials within 4 weeks prior to screening (or within 5 half-lives of the drug). * Blood donation/loss ≥400 mL or transfusion within 3 months prior to screening (excluding physiological blood loss in females). * Excessive alcohol consumption (\>14 units/week) within 4 weeks prior to screening (1 unit = 285 mL beer \[3.5%\], 25 mL spirits \[40%\], or 100 mL wine \[10%\]). * History of alcohol/drug abuse within 1 year prior to screening. * Pregnancy, lactation, or plans for pregnancy during the study. * Poor compliance (investigator's judgment). * Major surgery within 8 weeks prior to baseline or planned surgery during the study posing unacceptable risks. * Any other condition deemed by the investigator to compromise safety, validity, or suitability for the study.